1. A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.
- Author
-
Nath, Karthik, Shekarkhand, Tala, Salcedo, Meghan, Derkach, Andriy, Rueda, Siobhan, Chansakul, Aisara, Hulcrantz, Malin, Korde, Neha, Shah, Urvi A., Tan, Carlyn, Chung, David J., Lahoud, Oscar B., Hassoun, Hani, Lesokhin, Alexander M., Landau, Heather J., Shah, Gunjan, Scordo, Michael, Giralt, Sergio A., Usmani, Saad Z., and Roshal, Mikhail
- Subjects
MULTIPLE myeloma ,DARATUMUMAB ,DISEASE remission ,CLINICAL trials ,BONE marrow examination ,PLASMACYTOMA - Abstract
At last follow-up, 5 (50%) patients remained on maintenance lenalidomide, and 5 (50%) patients received a subsequent line of therapy (note: three patients, in the absence of PD, continued on daratumumab beyond the six cycles). It is plausible that in standard-risk patients there may be a stable MRD clone without clinical consequence, leading to clinician and patient preferences to avoid interventions in the absence of a clinical relapse. Despite the improved complete response (CR) rates in multiple myeloma with newer therapies, most patients still relapse [[1]]. Although there was a third patient that converted to bone marrow MRD-negativity, this patient had serologic progressive disease (PD) at the time of response assessment and was deemed not to have achieved the primary end point. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF